Figure 1.

Mutational data of 350 CBF AML patients by high-throughput targeted sequencing. (A) The incidence of recurrently mutated genes (>3%) by CBF-AML entity. Asterisks indicate significant differences between both CBF-AML entities. (B) Bar plot indicating the number of driver events by patient for all patients in each CBF-AML cohort. Dashed lines indicate the median number of mutations in each CBF-AML cohort. (C) Number of privately or commonly mutated genes by CBF-AML entity. (D) Pie charts representing mutation type distribution by CBF-AML cohort. (E) Molecular hotspots. Bar plots indicating proportion of affected mutational hotspots in NRAS, KIT, and FLT3 by CBF-AML cohort.